ArticleJACC. Advances2026
Sex Differences in Presentation and Outcomes of Transthyretin Amyloid Cardiomyopathy.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTransthyretin amyloid cardiomyopathy (ATTR-CM) is more often diagnosed in men than in women but sex-specific data remain limited.
objectivesThe objective of the study was to characterize sex-related differences in presentation and outcomes in patients with ATTR-CM.
methodsConsecutive prospective patients with confirmed ATTR-CM enrolled in the multicenter Swiss-CARE registry (February 2018-March 2025) were analyzed. Clinical data were obtained at diagnosis, 6 months postdiagnosis, and yearly thereafter. The primary endpoint was first major adverse cardiac event (MACE) (ie composite of heart failure hospitalization and all-cause mortality). Kaplan-Meier and Cox proportional hazards models were employed.
resultsAmong 567 patients with ATTR-CM (age 77 ± 7 years, 52 [9%] women), women were older at diagnosis (80.3 ± 6.1 vs 76.9 ± 6.9 years; P < 0.001), had a higher NYHA functional class (P < 0.001), higher N-terminal pro-B-type natriuretic peptide (2,574 vs 1,632 pg/mL; P = 0.006), and shorter 6-minute walking distance (320 ± 111 vs 411 ± 114 m; P = 0.001). Tafamidis was less frequently prescribed in women (50.0% vs 69.7%; P = 0.004). Women had a higher incidence of MACE (HR: 1.86; 95% CI: 1.13-3.04; P = 0.014), driven by increased heart failure hospitalizations within the first 2 years (HR: 2.21; 95% CI: 1.17-4.19; P = 0.015) and a trend toward higher all-cause mortality (HR: 1.82; 95% CI: 0.97-3.43; P = 0.06). In multivariable analyses, sex was not independently associated with MACE (P = 0.23).
conclusionsWomen exhibited a higher risk of MACE after diagnosis; however, sex was not an independent predictor of outcomes in multivariable analysis. This disadvantage in women may be partly explained by older age at diagnosis, higher NT-proBNP levels, greater symptom burden, and a higher prevalence of comorbidities, rather than intrinsic sex-specific differences in ATTR-CM progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.